Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: GlobeNewswire
BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Global Chief Commercial Officer, David W. Robinson. The awards were approved by Ocular’s Board of Directors and were made as inducements material to Mr. Robinson’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Robinson’s inducement equity awards were granted effective as of January 21, 2026, and consist of a non-statutory stock option award to purchase up to an aggregate of 416,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive an aggregate of 136,000 shares of Ocular’s common stock. The stock option award has an exercise price of $11.42 per share, equal to the closing pric
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial OfficerGlobeNewswire
- 3 Reasons OCUL is Risky and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales [Yahoo! Finance]Yahoo! Finance
- BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD [Yahoo! Finance]Yahoo! Finance
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 3
- 1/23/26 - Form 8-K
- OCUL's page on the SEC website